Regulatory clearances for two CAR-T therapies and one innovative antibody-drug conjugate during 2021 highlighted the acceleration of new drug approvals in China.
Throughout the year, the country’s drug approval agency the National Medical Products Administration (NMPA) granted the green light to a total of 43 innovative new therapies, with oncology products continuing to dominate
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?